article thumbnail

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

XTalks

With FDA approval granted, Humacyte is working to make Symvess widely available in hospitals, trauma centers and military facilities, offering new treatment options for patients with vascular injuries. Symvess does carry risks, including thrombosis, graft rupture and infection.

article thumbnail

US FDA approves GSK’s Jesduvroq to treat anaemia of CKD

Pharmaceutical Technology

Last December, GSK and Wave Life Sciences entered a strategic partnership to drive the discovery and development of oligonucleotide therapies for new genetic targets. The post US FDA approves GSK’s Jesduvroq to treat anaemia of CKD appeared first on Pharmaceutical Technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Ensacove (Ensartinib) for Advanced NSCLC in Crowded ALK Inhibitor Market

XTalks

It includes Roches Alecensa (alectinib), Takedas Alunbrig (brigatinib) and Pfizers third-generation Lorbrena (lorlatinib), which have all surpassed Xalkori in performance, leading to their respective FDA approvals for first-line treatment.

article thumbnail

Xtalks Life Science Podcast: Celebrating 200 Episodes of Industry Innovation

XTalks

This week, were celebrating a significant milestone: the release of our 200th episode of the Xtalks Life Science Podcast ! We’re excited to continue our journey by bringing you more in-depth conversations with industry leaders, highlighting the innovations and trends that shape the future of life sciences.

article thumbnail

FDA Approves First Fecal Matter Therapy + PureTech Reveals New CBD Oral Capsule – Xtalks Life Science Podcast Ep. 89

XTalks

In this episode, Ayesha talked about the FDA approval of Ferring Pharmaceuticals’ fecal matter-based therapy Rebyota for the treatment of recurrent C. Read the full articles here: FDA Approves Rebyota as First Fecal Microbiome Therapy for Recurrent C. difficile infections. Difficile Infection.

article thumbnail

Interview with Polarean Imaging CTO Dr. Bastiaan Driehuys on the FDA Approval of Lung Imaging Drug Device Combo Xenoview – Xtalks Life Science Podcast Ep. 97

XTalks

Bastiaan Driehuys, PhD Founder and Chief Technology Officer Polarean Imaging plc In this week’s Xtalks Life Science podcast episode, Ayesha and the editorial team spoke with Dr. Bastiaan Driehuys, Founder and Chief Technology Officer at Polarean Imaging plc. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

Ctexli (Chenodiol) Gains FDA Approval as First CTX Treatment

XTalks

Mirum Pharmaceuticals, a biotech innovator known for developing therapies for rare metabolic disorders, now has FDA approval for its new treatment, Ctexli (chenodiol) tablets the first and only medication approved for cerebrotendinous xanthomatosis (CTX) in adults.